This content is machine translated ACC 2018 Success story of PCSK9 inhibition continues For the first time after the highly acclaimed FOURIER trial, a PCSK9 inhibitor now also shows a mortality benefit in secondary prevention. The product in question is alirocumab. Experts are…
View Post 4 min This content is machine translated Allergo Update 2018, Cologne Biologics create new therapeutic perspectives Atopic dermatitis (AD) is considered complex, is allergen-mediated in most patients, and is associated with many comorbidities. Increasing knowledge of key inflammatory mediators has paved the way for new biologics…
View Post 4 min This content is machine translated DKK in Berlin - Leukemia treatment Revolution through personalized therapy Knowledge of molecular markers in leukemias could help identify high-risk patients in the future. In addition, there is an opportunity to develop further targeted therapeutic approaches. Some already approved therapeutics…
View Post 5 min This content is machine translated AAD 2018, San Diego From rare and common skin conditions Psoriasis therapy has been significantly expanded in recent years. New substances are continuously entering the market. Merkel cell carcinoma, on the other hand, is a rare skin tumor with a…
View Post 5 min This content is machine translated 13th Zurich Hypertension Day The difficult to adjust blood pressure 50% of hypertensives are not well controlled with prescribed medications, and about 40% of sufferers in Switzerland are not diagnosed at all. Thilo Burkard, MD, spoke at the Zurich Hypertension…
View Post 4 min This content is machine translated SWICA Symposium 2018, Bern Sleep disorders in old age Sleep disorders in old age can manifest in a cause-effect-cause spiral: Depression, cognitive disorders or dementia may correlate with sleep disorders. Dr. med. Roland Kunz, Zurich, explained these relationships, clarified…
View Post 6 min This content is machine translated 11th spring cycle in Lucerne Bronchial asthma in children and adolescents Childhood asthma management is now based on close patient follow-up, including self-management education. But is it asthma at all? A question to ask yourself first. Rates of overdiagnosis are high.…
View Post 5 min This content is machine translated ECCO 2018: New perspectives in CED therapy Chronic inflammatory bowel disease Chronic inflammatory bowel disease (IBD) remains difficult to control in the long term. Forty to 50 percent of IBD patients have frequent recurrences, reported Dr. Sharon Veenbergen from Rotterdam at the…
View Post 3 min This content is machine translated Interview with Prof. Edith Holsboer-Trachsler, Basel Depression: When medical professionals are affected Every fourth doctor in Switzerland feels burnt out. But where is there help for those who usually help? Prof. Edith Holsboer-Trachsler, Extraordinaria for Clinical Stress and Trauma Research, UPK Basel, and…
View Post 1 min This content is machine translated SGPP Annual Congress 2017, Bern - video lecture Video: Evidence-based pharmacotherapy for borderline personality disorder. 50% of patients with borderline personality disorder take three medications or more daily. This is surprising because there is insufficient validated empirical evidence for medication treatment of borderline personality disorder.
View Post 1 min This content is machine translated SGPP Annual Congress 2017, Bern - video lecture Video: Evidence-based psychotherapeutic practices for the treatment of borderline personality disorder. The “Big Four” therapies presented in this paper are among the most empirically studied disorder-specific therapies: Dialectical Behavioral Therapy (DBT), Schema Therapy (SFT), Mentalization-Based Therapy (MBT), and Transference-Focused Therapy (TFP).
